Latest Dunad Therapeutics News & Updates

See the latest news and media coverage for Dunad Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Dunad Therapeutics

Biotech developing covalent small-molecule therapies for neurodegenerative diseases

dunadtx.com

Headquarters: Cambridge, United States
Founded year: 2020
Company type: Private company
Number of employees: 10–50

Last updated Today

Latest news about Dunad Therapeutics

Company announcements

April 17 Dunad Therapeutics

Dunad Therapeutics announces Pearl Huang's induction into AIMBE Fellows

Pearl Huang, CEO and President, joins the top 2% of medical and biological engineers for her biotechnology innovation and leadership contributions.

February 26 Dunad Therapeutics

Dunad Therapeutics welcomes Dr. Stephen Huhn as CMO

Dr. Huhn brings extensive experience in neurodegenerative disorders, clinical development, and regulatory strategy. He previously served at Stanford University.

February 19 Dunad Therapeutics

Dunad Therapeutics nominates DUN’040 as development candidate for ALS

DUN’040 is a covalent PIKfyve inhibitor mitigating TDP-43 proteinopathy. It achieves high CNS exposure, survival benefit in preclinical studies, and wide therapeutic index. Dunad initiates IND-enabling studies for Phase I.

January 29 Dunad Therapeutics

Dunad Therapeutics announces Dr. Antony Burton's presentation

He will share insights on “Chemoproteomics discovery of a CNS-penetrant covalent inhibitor of PIKfyve” at the 2nd Proteomics-based Drug Discovery Summit in Boston, February 2-4.

Media coverage

9 January 2023 Vancouver Sun

Dunad Therapeutics Appoints Michael Bonney as Chair of Board of Directors

CAMBRIDGE, England — Dunad Therapeutics, a biopharmaceutical company developing covalent small molecule therapies with a focus on protein degradation, today announced the appointment of Michael...

23 February 2022 PharmaTimes

Novartis signs $1.3bn deal with UK-based Dunad

Dunad will apply its own platform to generate the novel covalent and targeted protein degrading small molecule drugs Novartis and Cambridge, UK-based Dunad Therapeutics have...

2 November 2021 PR Newswire

Dalriada Drug Discovery Celebrates Client Dunad Therapeutics Billion Dollar Collaboration with Novartis

Dalriada has worked with Dunad since its inception to support the development of its novel small molecule protein degradation modality Since its inception Dunad's R&D...

23 March 2021 PR Newswire

Dunad Therapeutics Emerges To Develop Next-generation Small Molecule Therapeutics Based On First Tuneable Targeted Protein Degradation Technology

CAMBRIDGE, England, March 23, 2021 /PRNewswire/ -- Dunad Therapeutics ("Dunad") emerges today to develop next-generation small molecule therapeutics based on its highly differentiated, tuneable and...

Never miss news about Dunad Therapeutics

Track Dunad Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Dunad Therapeutics competitors & trending companies

Browse news for competitors to Dunad Therapeutics and other trending companies.